Harrow reported second quarter 2026 revenue of $70.7 million, missing analyst estimates of $72.4 million, while producing a larger-than-expected adjusted EPS loss of $0.46. Despite the headline miss, the company's core branded product, VEVYE, showed significant commercial momentum with revenue growing 40% sequentially. Management reiterated full-year 2026 revenue guidance of $350 million to $365 million, signaling an expected sharp acceleration in the second half of the year.
Key Highlights
- VEVYE revenue reached $29.4 million, a 58% increase year-over-year, nearly doubling its branded market share to 14.6%.
- IHEEZO achieved record quarterly unit demand of 65,477 units, up 44% sequentially, despite losing pass-through reimbursement status for cataract surgery on April 1, 2026.
- TRIESENCE unit demand surged 162% year-over-year to 14,529 units, marking its strongest quarter since launch.
- The company announced the acquisition of global rights to TYRVAYA from Viatris, which is expected to contribute over $30 million in revenue in 2027.
- Cash and cash equivalents totaled $83.9 million as of June 30, 2026, compared to $72.9 million at the end of 2025.